207 related articles for article (PubMed ID: 32567459)
21. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
22. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
23. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.
Yamashita S; Hamamoto S; Furukawa J; Fujita K; Takahashi M; Miyake M; Ito N; Iwamoto H; Kohjimoto Y; Hara I
Sci Rep; 2024 May; 14(1):12398. PubMed ID: 38811687
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of nutritional status assessed by the Controlling Nutritional Status score in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
Wada H; Dohi T; Miyauchi K; Doi S; Konishi H; Naito R; Tsuboi S; Ogita M; Kasai T; Okazaki S; Isoda K; Suwa S; Daida H
Clin Res Cardiol; 2017 Nov; 106(11):875-883. PubMed ID: 28634674
[TBL] [Abstract][Full Text] [Related]
26. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study.
Toyokawa T; Kubo N; Tamura T; Sakurai K; Amano R; Tanaka H; Muguruma K; Yashiro M; Hirakawa K; Ohira M
BMC Cancer; 2016 Sep; 16(1):722. PubMed ID: 27599460
[TBL] [Abstract][Full Text] [Related]
27. Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.
Desideri I; Francolini G; Scotti V; Pezzulla D; Becherini C; Terziani F; Delli Paoli C; Olmetto E; Visani L; Meattini I; Greto D; Bonomo P; Loi M; Detti B; Livi L
Clin Transl Oncol; 2019 Jul; 21(7):933-938. PubMed ID: 30565084
[TBL] [Abstract][Full Text] [Related]
28. [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
Rexer H; Steiner T; Grünwald V
Urologe A; 2017 Apr; 56(4):509-511. PubMed ID: 28251253
[No Abstract] [Full Text] [Related]
29. Comparison of the Clinical Implications among Five Different Nutritional Indices in Patients with Lupus Nephritis.
Ahn SS; Yoo J; Jung SM; Song JJ; Park YB; Lee SW
Nutrients; 2019 Jun; 11(7):. PubMed ID: 31252552
[TBL] [Abstract][Full Text] [Related]
30. Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection.
Kuroda D; Sawayama H; Kurashige J; Iwatsuki M; Eto T; Tokunaga R; Kitano Y; Yamamura K; Ouchi M; Nakamura K; Baba Y; Sakamoto Y; Yamashita Y; Yoshida N; Chikamoto A; Baba H
Gastric Cancer; 2018 Mar; 21(2):204-212. PubMed ID: 28656485
[TBL] [Abstract][Full Text] [Related]
31. The Controlling Nutritional Status Score Serves as a Predictor of Short- and Long-Term Outcomes for Patients with Stage 2 or 3 Gastric Cancer: Analysis of a Multi-institutional Data Set.
Ryo S; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Ann Surg Oncol; 2019 Feb; 26(2):456-464. PubMed ID: 30565044
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.
Harimoto N; Yoshizumi T; Sakata K; Nagatsu A; Motomura T; Itoh S; Harada N; Ikegami T; Uchiyama H; Soejima Y; Maehara Y
World J Surg; 2017 Nov; 41(11):2805-2812. PubMed ID: 28653142
[TBL] [Abstract][Full Text] [Related]
34. Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.
Kim HL; Han KR; Zisman A; Figlin RA; Belldegrun AS
J Urol; 2004 May; 171(5):1810-3. PubMed ID: 15076282
[TBL] [Abstract][Full Text] [Related]
35. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
36. Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors.
Shin SJ; Kim T; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI; Kang M
Clin Genitourin Cancer; 2019 Dec; 17(6):e1137-e1146. PubMed ID: 31473122
[TBL] [Abstract][Full Text] [Related]
37. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
38. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
39. Controlling Nutritional Status score: A new prognostic indicator for patients with oligometastatic prostate cancer.
Zhang W; Wu Y; Zhang Z; Guo Y; Wang R; Wang L; Mao S; Zhang J; Yao X
Curr Probl Cancer; 2019 Oct; 43(5):461-470. PubMed ID: 30910226
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of Preoperative Controlling Nutritional Status (CONUT) Score in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma: A Multi-institutional Study.
Harimoto N; Yoshizumi T; Inokuchi S; Itoh S; Adachi E; Ikeda Y; Uchiyama H; Utsunomiya T; Kajiyama K; Kimura K; Kishihara F; Sugimachi K; Tsujita E; Ninomiya M; Fukuzawa K; Maeda T; Shirabe K; Maehara Y
Ann Surg Oncol; 2018 Oct; 25(11):3316-3323. PubMed ID: 30051372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
